CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 148 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $353,976 | +532.1% | 56,276 | +232.9% | 0.00% | – |
| Q4 2021 | $56,000 | -13.8% | 16,904 | -0.0% | 0.00% | – |
| Q3 2021 | $65,000 | +54.8% | 16,906 | +73.2% | 0.00% | – |
| Q1 2021 | $42,000 | -65.3% | 9,759 | -47.3% | 0.00% | – |
| Q4 2020 | $121,000 | +51.2% | 18,530 | +68.1% | 0.00% | – |
| Q3 2020 | $80,000 | +81.8% | 11,020 | -17.2% | 0.00% | – |
| Q2 2020 | $44,000 | +2100.0% | 13,309 | +698.4% | 0.00% | – |
| Q1 2020 | $2,000 | -88.2% | 1,667 | -80.9% | 0.00% | – |
| Q4 2019 | $17,000 | -94.6% | 8,747 | -85.6% | 0.00% | – |
| Q3 2019 | $312,000 | +550.0% | 60,877 | +799.1% | 0.00% | – |
| Q2 2019 | $48,000 | +700.0% | 6,771 | +1372.0% | 0.00% | – |
| Q1 2019 | $6,000 | -14.3% | 460 | -44.4% | 0.00% | – |
| Q4 2018 | $7,000 | 0.0% | 828 | +38.9% | 0.00% | – |
| Q3 2018 | $7,000 | +16.7% | 596 | +42.6% | 0.00% | – |
| Q2 2018 | $6,000 | – | 418 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |